At Almac, we realise our client partners face a variety of business challenges from changing clinical trial plans to forecasting difficulties particularly for specialised medicines and orphan drug products and as such, we differentiate ourselves by offering the flexibility that clients need.
This case study is an example of our ‘Reserved Technology Capacity’ business model and provides an overview of:
The strategic partnership established between Almac and a global Big Pharma company
How moving from a transactional fee for service model benefited our client partner allowing them to have dedicated capacity on key technology to support their clinical trials
At Almac, we realise our client partners face a variety of business challenges from changing clinical trial plans to forecasting difficulties particularly for specialised medicines and orphan drug products and as such, we differentiate ourselves by offering the flexibility that clients need.
